{"title":"Chronic Kidney Disease in China: Addressing the Burden With Innovative Strategies and Global Insights.","authors":"Xiaoqiang Ding","doi":"10.1002/dmrr.70092","DOIUrl":null,"url":null,"abstract":"<p><p>Chronic kidney disease (CKD) is a major global public health concern, increasing end-stage renal disease (ESRD) prevalence and risks of cardiovascular events and mortality. Approximately 82 million adults in China are affected by CKD, with highly prevalent and poorly controlled comorbidities such as hypertension, diabetes, and dyslipidemia. Novel agents have been approved for clinical use in China such as non-steroidal mineralocorticoid receptor antagonists (nsMRAs) like finerenone and sodium-glucose cotransporter-2 inhibitors (SGLT2is) provide dual 'cardiorenal' protection, slowing kidney disease progression through anti-inflammatory or metabolic modulation. This special issue of China features five representative studies on key CKD questions, covering endothelial dysfunction mechanisms, early detection of tubular injury in diabetic kidney disease, real-world efficacy of finerenone, and clinical advances in multi-target therapies. These studies collectively underscore China's contributions to advancing CKD research and improving patient management globally.</p>","PeriodicalId":48934,"journal":{"name":"Diabetes-Metabolism Research and Reviews","volume":"41 7","pages":"e70092"},"PeriodicalIF":6.0000,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Diabetes-Metabolism Research and Reviews","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1002/dmrr.70092","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Chronic kidney disease (CKD) is a major global public health concern, increasing end-stage renal disease (ESRD) prevalence and risks of cardiovascular events and mortality. Approximately 82 million adults in China are affected by CKD, with highly prevalent and poorly controlled comorbidities such as hypertension, diabetes, and dyslipidemia. Novel agents have been approved for clinical use in China such as non-steroidal mineralocorticoid receptor antagonists (nsMRAs) like finerenone and sodium-glucose cotransporter-2 inhibitors (SGLT2is) provide dual 'cardiorenal' protection, slowing kidney disease progression through anti-inflammatory or metabolic modulation. This special issue of China features five representative studies on key CKD questions, covering endothelial dysfunction mechanisms, early detection of tubular injury in diabetic kidney disease, real-world efficacy of finerenone, and clinical advances in multi-target therapies. These studies collectively underscore China's contributions to advancing CKD research and improving patient management globally.
期刊介绍：
Diabetes/Metabolism Research and Reviews is an indispensable resource for clinicians and researchers working in the fields of diabetes, endocrinology, metabolism and obesity. Our reviews section provides the latest updates on clinical and basic scientific advances in key areas of diabetes, obesity and metabolism, important historical overviews, discussion of controversial issues and opinions from prominent researchers and clinicians. Original articles describing clinical studies, translational and basic research related to diabetes, obesity, metabolism, or closely related metabolic disorders are welcome, as are articles concerned with treatment and management issues related to patient care.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
